Regulation & Policy
MHRA introduces new antidepressant warnings on suicidal thoughts and persistent sexual dysfunction
The MHRA is adding a boxed warning to patient leaflets, a patient card and a safety leaflet due in 2027. The measures follow a review involving patients and families.

The Medicines and Healthcare products Regulatory Agency (MHRA) has begun implementing new safety measures to improve how patients are told about the risks of suicidal thoughts and behaviours and persistent sexual dysfunction with antidepressants. The agency set out the changes in a Drug Safety Update published on 15 October 2026.
According to the MHRA, the measures follow a detailed review, involving patients and their families, of how these risks are communicated in patient information leaflets (PILs). The changes comprise a new boxed warning in the PIL, a new patient card and a supporting safety (ancillary) leaflet. The term "post SSRI sexual dysfunction" (PSSD) will also be added to PILs for some antidepressants.
What is changing
The boxed warning will highlight information on suicidal thoughts and behaviours and signpost where patients can get help. The patient card will be available in digital or hard copy form. The MHRA expects the hard copy to be credit-card sized. Initially it will be available electronically, and dispensers may give it to patients as an interim measure.
PSSD will be added to the PILs of antidepressants associated with a risk of sexual dysfunction that may continue after the drug is stopped. The MHRA lists ten medicines in this group, including citalopram, sertraline, venlafaxine and amitriptyline.
The safety leaflet is being developed jointly with other healthcare system partners and will cover benefits, risks and alternatives. It is intended to be given at the first consultation for new patients, or the next consultation for existing patients. The MHRA said it will be available in 2027.
Advice and background
The MHRA advises healthcare professionals to discuss these risks with patients when starting or changing the dose of an antidepressant, or at the next review. It also advises following relevant NICE guidance, monitoring patients regularly and reporting suspected adverse reactions through the Yellow Card scheme. Its patient advice states that these are not new risks and that people should not stop their medicine without speaking to a healthcare professional.
A Commission on Human Medicines (CHM) Expert Working Group was convened after patients and families raised concerns about whether PILs adequately communicate these risks. It met between May 2024 and July 2025, and the CHM considered its recommendations in September 2025. The MHRA then worked with the Patients Association, which brought together a patient focus group to refine the wording and format of the PILs.
The MHRA said it is coordinating further actions over the coming months. These include considering updates to NICE guidelines and the British National Formulary, and work with the Royal Colleges of General Practice, Psychiatrists and Pharmacy, and NHS guidance. A Public Assessment Report describing the data the working group considered is now available.
Why it matters
Changes to patient information leaflets could require marketing authorisation holders to update product materials, although the source gives no timelines for this. The 2027 safety leaflet and the planned NICE, BNF and NHS guidance work are likely to affect how prescribers and pharmacy teams structure antidepressant consultations. Digital and printed patient cards may also create demand for supporting tools in primary care and dispensing.
Source: MHRA
Related stories

Regulation & Policy
MHRA publishes 2026–2030 plan to widen patient involvement in regulation

Regulation & Policy
MHRA grants conditional approval to triheptanoin for rare inherited fatty acid disorders

Regulation & Policy
MHRA extends Casgevy approval to children aged five and over with sickle cell disease and β-thalassaemia